Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study

Autoimmune thyroid disease (AITD) is the most common adverse effect in alemtuzumab (ALZ) treated relapsing–remitting (RR) multiple sclerosis (MS) patients. The objective of this prospective study was to analyze the occurrence, timing of onset, clinical course, and laboratory characteristics of AITD...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazakou, Paraskevi, Tzanetakos, Dimitrios, Vakrakou, Aigli G., Tzartos, John S., Evangelopoulos, Μaria-Eleptheria, Anagnostouli, Maria, Stathopoulos, Panos, Kassi, Georgia N., Stefanis, Leonidas, Kilidireas, Constantinos, Zapanti, Evangelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543528/
https://www.ncbi.nlm.nih.gov/pubmed/36641771
http://dx.doi.org/10.1007/s10238-022-00981-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543528/
https://www.ncbi.nlm.nih.gov/pubmed/36641771
http://dx.doi.org/10.1007/s10238-022-00981-3

Ejemplares similares